News
Kromann Reumert assists Orifarm in acquisition of pharmaceutical products and manufacturing sites from Takeda for up to EUR 615 million
Kromann Reumert advises Danish pharmaceutical company Orifarm on its acquisition of pharmaceutical products and manufacturing sites from Japanese pharmaceutical company Takeda for up to EUR 615 million.
Kromann Reumert has been advising Orifarm during the entire transaction. The transaction includes 110 pharmaceutical products and two manufacturing sites in Denmark and in Poland. It is the largest acquisition ever made by Orifarm.
The transaction is conditional upon regulatory approvals with closing expected in March 2021 at the latest.
Practice areas
Industries
Contact
Partner (Copenhagen)
Dir. +45 38 77 45 35
Mob. +45 40 25 11 15
Partner (Copenhagen)
Dir. +45 38 77 46 06
Mob. +45 61 20 11 74